课题基金 / 基金详情

Development of novel agents for the treatment of amyotrophic lateral sclerosis: Discovery and proof-of-concept

Development of novel agents for the treatment of amyotrophic lateral sclerosis: Discovery and proof-of-concept
治疗肌萎缩侧索硬化症的新药的开发：发现和概念验证
批准号：
477327
负责人：
Tranmer Geoffrey
金额：
$7.29万
依托单位：
University of Manitoba
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
已结题
起止时间：
2022-10-01 至 2023-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=477327&lang=en
关键词：
Amyotrophic Lateral Sclerosis Antioxidants Boron Medicinal Chemistry Edaravone Nsc-34 Cell Lines Primary Cortical Neuron Culture Sod1 Sod1-G37r Mouse Model

项目摘要

项目成果

Tranmer Geoffrey的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Although amyotrophic lateral sclerosis (ALS) has been known as a major neurodegenerative disease for decades, very few drugs have been approved for the treatment of ALS. Additionally, with the increasing incidence and prevalence of ALS, there is a great n
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identification and development of an industry partnership for the invention of diagnostic tools to address antimicrobial resistance
  • 批准号：
    349743
  • 项目类别：
    Operating Grants
  • 资助金额：
    $0.57万
  • 财政年份：
    2016
  • 负责人：
    Tranmer Geoffrey
  • 依托单位：
    University of Manitoba
海外基金